{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:15:08Z","timestamp":1783685708767,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health at Charit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.adro.2026.102059","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:36:01Z","timestamp":1776238561000},"page":"102059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac Dose and Survival Outcomes Following Stereotactic Body Radiation Therapy for Primary and Metastatic Lung Tumors: A Substructure-Based Analysis"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3798-1546","authenticated-orcid":false,"given":"Goda","family":"Kalinauskaite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"F\u00fcchtbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Rubarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh-Thao","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Silvana","family":"Kilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Mehrhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Senger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2026.102059_bib0001","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial\u2014a prospective nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.adro.2026.102059_bib0002","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102059_bib0003","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ijrobp.2023.06.246","article-title":"Expanded HILUS trial: A pooled analysis of risk factors for toxicity from stereotactic body radiation therapy of central and ultracentral lung tumors","volume":"117","author":"Lindberg","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102059_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109848","article-title":"Ten years outcomes after SABR in central and ultracentral primary lung tumors","volume":"188","author":"Tekatli","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.102059_bib0005","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","article-title":"Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree","volume":"6","author":"Haseltine","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102059_bib0006","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2008.12.016","article-title":"Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus","volume":"66","author":"Song","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.adro.2026.102059_bib0007","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non\u2013small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102059_bib0008","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2017.07.053","article-title":"Radiation dose to heart base linked with poorer survival in lung cancer patients","volume":"85","author":"McWilliam","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.adro.2026.102059_bib0009","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jtho.2022.09.004","article-title":"Cardiac function modifies the impact of heart base dose on survival: A voxel-wise analysis of patients with lung cancer from the PET-plan trial","volume":"18","author":"Craddock","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.adro.2026.102059_bib0010","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.radonc.2017.04.017","article-title":"Dose to heart substructures is associated with non-cancer death after SBRT in stage I\u2013II NSCLC patients","volume":"123","author":"Stam","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.102059_bib0011","article-title":"Dosimetric analysis of 17 cardiac sub-structures, toxicity, and survival in ultra central lung tumor patients treated with SBRT","volume":"43","author":"Ahmadsei","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102059_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2019.10.010","article-title":"Effect of radiation doses to the heart on survival for stereotactic ablative radiotherapy for early-stage non\u2013small-cell lung cancer: An artificial neural network approach","volume":"21","author":"Chan","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.adro.2026.102059_bib0013","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1016\/j.cllc.2017.08.002","article-title":"Survival impact of cardiac dose following lung stereotactic body radiotherapy","volume":"19","author":"Wong","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.adro.2026.102059_bib0014","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.ijrobp.2020.07.1289","article-title":"Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with inoperable stage I\/IIA non\u2013small-cell lung cancer (NSCLC): KEYNOTE-867","volume":"108","author":"Jabbour","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102059_bib0015","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM task group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.adro.2026.102059_bib0016","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102059_bib0017","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4236\/jct.2021.127036","article-title":"Impact of cardiac dose on overall survival in lung stereotactic body radiotherapy (SBRT) compared to conventionally fractionated radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC)","volume":"12","author":"Anderson","year":"2021","journal-title":"J Cancer Ther"},{"key":"10.1016\/j.adro.2026.102059_bib0018","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cllc.2016.12.007","article-title":"Cardiac dose and survival after stereotactic body radiotherapy for early-stage non\u2013small-cell lung cancer","volume":"18","author":"Tembhekar","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.adro.2026.102059_bib0019","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.21037\/jtd.2018.04.42","article-title":"Cardiac radiation dose distribution, cardiac events and mortality in early-stage lung cancer treated with stereotactic body radiation therapy (SBRT)","volume":"10","author":"Reshko","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.adro.2026.102059_bib0020","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.chest.2021.12.667","article-title":"Risk of cardiovascular toxicity according to tumor laterality among older patients with early stage non-small cell lung cancer treated with radiation therapy","volume":"161","author":"Liu","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.adro.2026.102059_bib0021","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/j.prro.2023.09.005","article-title":"Sinoatrial node dose is associated with worse survival in patients undergoing definitive stereotactic body radiation therapy for central lung cancers","volume":"14","author":"Iovoli","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102059_bib0022","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.clon.2024.07.005","article-title":"Cardiac substructure dose and survival in stereotactic radiotherapy for lung cancer: Results of the multi-centre SSBROC trial","volume":"36","author":"Chin","year":"2024","journal-title":"Clin Oncol"},{"key":"10.1016\/j.adro.2026.102059_bib0023","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.ijrobp.2024.07.1798","article-title":"Dose to the cardiac substructures\/great vessels and survival in patients treated with definitive stereotactic body radiation therapy for lung tumors \u2013 a pilot study","volume":"120","author":"Buchberger","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102059_bib0024","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109426000667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109426000667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:27:35Z","timestamp":1783682855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109426000667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2452109426000667"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2026.102059","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Dose and Survival Outcomes Following Stereotactic Body Radiation Therapy for Primary and Metastatic Lung Tumors: A Substructure-Based Analysis","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2026.102059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102059"}}